S-Adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial

Journal of Hepatology

Volumn 30, Issue 6, 1999, Pages 1081-1089

  Mato, Jose M ^a   Cámara, Javier ^b   Paz, Javier Fernández De ^c   Caballería, Llorenç ^d   Coll, Susana ^e   Caballero, Antonio ^f   García Buey, Luisa ^g   Beltrán, Joaquín ^h   Benita, Vicente ^c   Caballería, Joan ^d   Solà, Ricard ^e   Moreno Otero, Ricardo ^g   Barrao, Félix ^h   Martín Duce, Antonio ^c   Correa, Jose A ^g   Parés, Albert ^d   Barrao, Elena ^h   García Magaz, Inmaculada ^b   Puerta, Jose Luis ^b   Moreno, Jorge ^b   Boissard, Gabrielle ⁱ   Ortiz, Pablo ^b   Rodés, Joan ^d   more..

^a Lab of Vasc Biology and Thrombosis   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

ⁱ Department of Oncology   (Italy)

Author keywords

AdoMet; Alcohol; Cirrhosis; S adenosylmethionine

Indexed keywords

S ADENOSYLMETHIONINE;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LIVER FUNCTION; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

EID: 0344867846     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80263-3     Document Type: Article

References (42)

1. Kotb M, Mudd SH, Mato JM, Geller AM, Kredich NM, Cantoni G. Consensus nomenclature for the mammalian methionine adenosyltransferase genes and gene products. Trends Genet (England). 13:1977;51-52.
2. Mato JM, Alvarez L, Ortiz P, Pajares MA. S-Adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther. 73:1997;265-280.
3. Mudd SH, Poole JR. Labile methyl balances for normal humans on various dietary regimens. Metabolism. 24:1975;721-735.
4. Gil B, Casado M, Pajares MA, Boscá L, Mato JM, Martín-Sanz P, et al. Differential expression pattern of S-adenosylmethionine synthetase isoenzymes during rat liver development. Hepatology. 24:1996;876-881.
5. Cabrero C, Puerta J, Alemany S. Purification and comparison of two forms of S-adenosyl-L-methionine synthetase from rat liver. Eur J Biochem. 170:1987;299-304.
6. Alvarez L, Mingorance J, Pajares MA, Mato JM. Expression of rat liver S-adenosylmethionine synthetase in Escherichia coli results in two active oligomeric forms. Biochem J. 301:1994;557-561.
7. Martín Duce A, Ortiz P, Cabrero C, Mato JM. S-Adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology. 8:1988;65-68.
8. Cabrero C, Martín Duce A, Ortiz P, Alemany S, Mato JM. Specific loss of the high-molecular-weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. Hepatology. 8:1988;1530-1534.
9. Gaull GE, Tallan HH, Lonsdale D, Pryrembel H, Schaffner F, von Bassewitz DB. Hypermethioninemia associated with methionine adenosyltransferase deficiency: clinical, morphological and biochemical observations on four patients. J Pediatr. 98:1981;734-741.
10. Avila MA, Mingorance J, Martínez-Chantar ML, Casado M, Martín-Sanz P, Bosca L, et al. Regulation of rat liver S-adenosyl-methionine synthetase during septic shock: role of nitric oxide. Hepatology. 25:1997;391-396.
11. Sánchez-Góngora E, Ruiz F, Mingorance J, An W, Corrales FJ, Mato JM. Interaction of liver methionine adenosyl transferase with hydroxyl radicals. FASEB J. 11:1997;1013-1019.
12. Kinsell LW, Harper HA, Marton HC, Michael GD, Weiss HA. Rate of disappearance from plasma of intravenously administered methionine in patients with liver damage. Science. 106:1947;589-590.
13. Horowitz JH, Rypins EB, Henderson JM, Heymsfield SB, Moffitt SD, Hain RP, et al. Evidence for impairment of transsulfuration pathway in cirrhosis. Gastroenterology. 81:1981;668-675.
14. Vendemiale G, Altomare E, Trizio T, Le Grazie C, Di Padova C, Salerno MT, et al. Effect of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol. 24:1989;407-415.
15. 4-induced S-adenosylmethionine synthetase inactivation and attenuates liver injury. Hepatology. 16:1992;1022-1027.
16. Varela-Moreiras G, Alonso-Aperte E, Rubio M, Gassó M, Deulofeu R, Alvarez L, et al. Carbon tetrachloride-induced hepatic injury is associated with global DNA hypomethylation and homocysteinemia: effect of S-adenosylmethionine treatment. Hepatology. 22:1995;1310-1315.
17. Gassó M, Rubio M, Varela-Moreiras G, Cabré M, Caballería J, Alonso E, et al. Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. J Hepatol. 25:1996;200-205.
18. Stramentinoli G, Pezzoli C, Galli-Kienle M. Protective role of S-adenosyl-L-methionine against acetaminophen-induced mortality and hepatotoxicity in mice. Biochem Pharmacol. 28:1979;3567-3571.
19. Bray GP, Tredger M, Williams R. S-Adenosylmethionine protects against acetaminophen hepatotoxicity in two mouse models. Hepatology. 15:1992;297-301.
20. Stramentinoli G, Gulano M, Ideo G. Protective role of S-adenosyl-L-methionine on liver damage induced by D-galactosamine in rats. Biochem Pharmacol. 27:1978;1431-1433.
21. Feo F, Pascale R, Garcea R, Daino L, Pirsi L. Effect of the variations of S-adenosyl-L-methionine liver content on fat accumulation and ethanol metabolism in ethanol-intoxicated rats. Toxicol Appl Pharmacol. 83:1986;331-341.
22. +) ATPase. Protective effect of S-adenosyl-L-methionine, and N-acetylcysteine. Toxicol Appl Pharmacol. 97:1989;216-229.
23. García-Ruiz C, Morales A, Colell A, Ballesta A, Rodés J, Kaplowitz N, et al. Feeding S-adenosyl-L-methionine attenuates both ethanol-induced depletion of mitochondrial glutathione and mitochondrial dysfunction in periportal and perivenous rat hepatocytes. Hepatology. 21:1995;207-214.
24. Dunne JB, Davenport M, Williams R, Tredger JM. Evidence that S-adenosylmethionine and N-acetylcysteine reduce injury from sequential cold and warm ischaemia in the isolated perfused rat liver. Transplantation. 57:1994;1161-1168.
25. Stramentinoli G, Di Padova C, Gualano M, Rovagnati P, Galli-Kienle M. Ethynylestradiol-induced impairment of bile secretion in the rat: protective effects of S-adenosyl-L-methionine and its implication in estrogen metabolism. Gastroenterology. 80:1981;154-158.
26. Di Padova C, Di Padova F, Tritapepe R, Stramentinoli G. S-Adenosyl-L-methionine protection against alfa-naphthyl-isothiocyanate-induced cholestasis in the rat. Toxicol Lett. 29:1985;131-136.
27. Osada J, Aylagas J, Sánchez-Vegazo I, Gea T, Millán I, Palacios-Alaiz E. Effect of S-adenosyl-L-methionine on thioacetamide-induced liver damage in rats. Toxicol Lett. 32:1986;97-106.
28. Fernández E, Galán AI, Morán D, González-Buitrago JM, Muñoz ME, Jiménez R. Reversal of cyclosporine A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats. J Pharmacol Ther. 275:1995;114-119.
29. Cincu RN, Rodriguez-Ortigosa CM, Vesperinas I, Quiroga J, Prieto J. S-Adenosyl-L-methionine protects the liver against the cholestatic, cytotoxic, and vasoactive effects of leukotriene D4: a study with isolated and perfused rat liver. Hepatology. 26:1997;330-335.
30. Lieber CS, Casini A, DeCarli LM, Kim C, Lowe N, Sasaki R, et al. S-Adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology. 11:1990;165-172.
31. Frezza M, Tritapepe R, Pozzato G, Di Padova C. Prevention by S-adenosylmethionine of estrogen-induced hepatobiliary toxicity in women. Am J Gastroenterol. 83:1988;1098-1102.
32. Ribalta J, Reyes H, González MC, Iglesias J, Arrese M, Pontia J, et al. S-Adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology. 13:1991;1084-1089.
33. Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis: a double-blind, placebo controlled study. Gastroenterology. 99:1990;211-215.
34. Giudici GA, Le Grazie C, Di Padova C. The use of ademethionine (SAMe) in the treatment of cholestatic liver disorders. Metanalysis of clinical trials. Mato JM, Lieber C, Kaplowitz N, Caballero A, . Methionine Metabolism: Molecular Mechanism and Clinical Implications. 1992;67-79 CSIC Press, Madrid.
35. Pugh RNH, Murray-Lyon M, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:1973;646-649.
36. Caballería L, Parés A, Montull S, Piera C, Caballería J, Bruguera M, et al. Prognostic value of the aminopyrine breath test and abstinence in severe alcoholic liver disease. J Hepatol. 21:((suppl 1)):1994;S81.
37. Borowsky SA, Strome S, Lott E. Continued heavy drinking and survival in alcoholic cirrhotics. Gastroenterology. 80:1981;1405-1409.
38. Parés A, Barrera JM, Caballería J, Ercilla G, Bruguera M, Caballería L, et al. Hepatitis C virus antibodies in chronic alcoholics. Association with the severity of liver disease. Hepatology. 12:1990;1295-1299.
39. Takase S, Tsutsumi M, Kawahara H, Takada N, Takada A. The alcohol-related membrane antibody and hepatitis C virus infection in the progression of alcoholic liver disease. Hepatology. 17:1993;9-13.
40. Boyer JL, Ransohoff DF. Is colchicine effective therapy for cirrhosis? N Engl J Med. 318:1988;1751-1752.
41. Marchesini G, Bugianesi E, Bianchi G, Fabbri A, Marchi E, Zoli M, et al. Defective methionine metabolism in cirrhosis: relation to severity of liver disease. Hepatology. 16:1992;149-155.
42. Mezey E. Treatment of alcoholic liver disease. Semin Liver Dis. 13:1993;210-216.